| Pharmacokinetics of Alglucosidase Alfa in Patients With Pompe Disease (NCT01410890) | Genzyme, a Sanofi Company | 2014-11-03 |
| Safety and Efficacy Evaluation of Repeat neoGAA Dosing in Late Onset Pompe Disease Patients. (NCT01898364) | Genzyme, a Sanofi Company | 2013-08-19 |
| A Noninferiority Study of Alglucosidase Alfa Manufactured at the 160 L and 4000 L Scales in Treatment Naïve Patients With Infantile-Onset Pompe Disease (NCT01597596) | Genzyme, a Sanofi Company | 2012-08-01 |
| Exploratory Muscle Biopsy Assessment Study in Patients With Late-Onset Pompe Disease Treated With Alglucosidase Alfa (NCT01288027) | Genzyme, a Sanofi Company | 2011-06-01 |
| Immune Tolerance Induction Study (NCT00701701) | Genzyme, a Sanofi Company | 2008-12-14 |
| Growth and Development Study of Alglucosidase Alfa (NCT00486889) | Genzyme, a Sanofi Company | 2008-08-26 |
| Pompe Pregnancy Sub-Registry (NCT00567073) | Genzyme, a Sanofi Company | 2007-06-18 |
| Late-Onset Treatment Study Extension Protocol (NCT00455195) | Genzyme, a Sanofi Company | 2007-03-01 |
| Safety and Effectiveness Study of rhGAA in Patients With Advanced Late-Onset Pompe Disease Receiving Respiratory Support (NCT00268944) | Genzyme, a Sanofi Company | 2005-12-01 |
| A Placebo-Controlled Study of Safety and Effectiveness of Myozyme (Alglucosidase Alfa) in Patients With Late-Onset Pompe Disease (NCT00158600) | Genzyme, a Sanofi Company | 2005-09-01 |
| A Study of rhGAA in Patients With Late-Onset Pompe Disease (NCT00250939) | Genzyme, a Sanofi Company | 2005-02-01 |
| Extension Study of Long-term Safety and Efficacy of Myozyme for a Single Patient With Pompe Disease Who Were Previously Enrolled in Genzyme Sponsored ERT Studies. (NCT00765414) | Genzyme, a Sanofi Company | 2003-04-01 |
| Alglucosidase Alfa Temporary Access Program (NCT00520143) | Genzyme, a Sanofi Company | |